Virtual Library
Start Your Search
Andreina Brugnini
Author of
-
+
FP12 - Tumor Biology and Systems Biology - Basic and Translational Science (ID 188)
- Event: WCLC 2020
- Type: Posters (Featured)
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
FP12.08 - The Survival Impact of Circulating T Regulatory Cells Subsets in Patients with Untreated Lung Cancer (ID 3425)
00:00 - 00:00 | Author(s): Andreina Brugnini
- Abstract
Introduction
Regulatory T Cells (Tregs) play an important role in carcinogenesis and tumor escape from immunosurveillance by suppressing effector cells. The number of circulating Tregs are increased in patients with cancer, included lung cancer. However, the prognosis impact of different subsets in lung cancer prognosis it is limited and controversial. This study aimed to investigated survival impact of different circulatory Tregs subsets in patients with lung cancer
Methods
We analyzed the frequency of circulating CD4, CD8 and Tregs lymphocytes in 66 patients with lung cancer and 32 healthy controls using flow cytometry. Circulating Tregs subtypes: naïve, memory and the expression of the activation marker HLA-DR were correlated with overall survival. Statistical analysis was performed using the software SPSS 25.
Results
Sixty-six treatment-naïve lung cancer patients and 32 controls were enrolled to the study. The percentage of Tregs was significantly increased in lung cancer patients compared to healthy controls (7.23 vs 3.5 %, p<0,0001). There was significant difference between the percentage of memory Tregs (CD45RO+) in patients and controls (86.41 vs 43.21%; p<0.0001). Median Overall survival (OS) for all patients was 5,6 months, with a 12-months overall survival rate of 32,8%. We found that patients levels of Tregs above the 75th percentile (5.4 %) had a significantly worse OS than patients with levels below the 75th percentile (median OS 6.0 months vs 11.7 months; p 0.005; fig 1). Patients with more than 20% of activated Tregs (TRegs DR+) had worse OS than patients with lower levels (median OS 6.4 vs 11.8 months; p 0.003; Fig. 2). No association was found between memory Tregs (CD45 RO+) levels and survival.
Conclusion
Tregs and activated Tregs (DR+) are potential prognostic factors in patients with lung cancer and could be considered a predictive biomarker in future clinical trials.